Astellas Pharma Inc (ALPMF) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you very much for your attendance in this twenty fiscal twenty twenty five earnings call by Astellas Inc. I am Kato, Chief Communications and IR Officer. I would like to serve as a moderator for today. Following our presentation today, we will move on to the Q and A session. The presentation will be based on the presentation materials available on our website. Simultaneous interpretation in Japanese and English will be provided throughout the event, including the Q and A session. Please note that we cannot guarantee the accuracy of it. You can select your preferred language from the menu at the top of the Zoom webinar screen. If you select the original language, you will be able to listen to the audio in the original language without simultaneous interpretation. This is some note from us. This material, oral presentation and answers and statement in the Q and A session includes forward looking statements based on assumptions and beliefs in light of the information currently available to management and subject to significant risks and uncertainties. Actual financial results may differ materially depending on a number of factors. They contain information of pharmaceuticals including compounds under development, but this information is not intended to make any advertisements nor provide medical advice of any kind. Now let me introduce you the participants from Astellas here today. Naoki Okamura, President and CEO Clinical Research and Development Officer, Tadaki Taniguchi Chief Commercial and Medical Affairs Officer, Klaus Seiler CFO, Atsushi Kitamura. So these four are attending in this meeting. Now I would like to start the presentation of Kamura's and the floor is yours. Hello, everyone. I'm Naoki Okamura from Astellas Pharma Inc. Thank you very much for joinin...